Efficacy of Adjuvant Chemotherapy for Fatty Acid Synthase-Positive and Negative Distal Bile Duct Cancer and Ampullary Cancer: A Retrospective Analysis

H. Maekawa, Koich Sato
{"title":"Efficacy of Adjuvant Chemotherapy for Fatty Acid Synthase-Positive and Negative Distal Bile Duct Cancer and Ampullary Cancer: A Retrospective Analysis","authors":"H. Maekawa, Koich Sato","doi":"10.4172/1948-5956.1000584","DOIUrl":null,"url":null,"abstract":"Objective: Immunohistochemical fatty acid synthase expression is a prognostic marker in several cancers and is related to cancer aggressiveness. Here, we analyzed fatty acid synthase expression as an indicator of adjuvant chemotherapy for distal bile duct and ampullary cancer cases. Methods: Forty-three cases of distal bile duct cancer and thirty-seven ampullary cancer cases resected between 2000 and 2017 were examined. We investigated immunohistochemical fatty acid synthase expression in resected specimens and the involvement of lymph nodes. We compared these findings with patient prognosis using medical history of postoperative adjuvant chemotherapy. Patient survival was expressed by the Kaplan-Meyer method and analyzed by a log-rank test. Results: There were twenty-two fatty acid synthase-positive cases for distal bile duct cancer and seventeen for ampullary cancer. For distal bile duct cancer cases, the relapse-free survival and overall survival of fatty acid synthase-positive cases were shorter than those for fatty acid synthase-negative cases (p=0.0094 and p=0.0327, respectively). For ampullary cancer cases, the relapse-free survival and overall survival of fatty acid synthasepositive cases were also shorter than those for fatty acid synthase-negative cases (p=0.0225 and p=0.0103, respectively). Adjuvant chemotherapy occurred in twelve of the twenty-two fatty acid-positive distal bile duct cancer cases and in eight of the seventeen fatty acid-positive ampullary cancer cases. Relapse-free survival and overall survival of cases with adjuvant chemotherapy did not differ from those without adjuvant chemotherapy in both distal bile duct cancer and ampullary cancer. Conclusion: Although fatty acid synthase expression was a prognostic factor in bile duct cancer and ampullary cancer, it was not an indicating marker for adjuvant chemotherapy. Citation: Maekawa H, Sato K (2019) Efficacy of Adjuvant Chemotherapy for Fatty Acid Synthase-Positive and Negative Distal Bile Duct Cancer and Ampullary Cancer: A Retrospective Analysis. J Cancer Sci Ther 11: 057-062. doi: 10.4172/1948-5956.1000584 J Cancer Sci Ther, an open access journal ISSN: 1948-5956 Volume 11(2) 057-062 (2019) 58 Figure 2: The prognoses of distal bile duct cancer according to node involvement (A) Relapse-free survival curve of node-positive and -negative cases, the relapsefree survival of node-positive cases was shorter than that of node-negative cases (50% relapse-free survival was 7 months and undefined, respectively, p=0.0002) (B) Overall survival curve of node-positive and -negative cases, there was no significant difference between node-positive cases and node-negative cases (mean survival time was 22 months and 60 months, respectively, p=0.0925). Figure 1: Immunohistochemical FAS expression (A) FAS staining of adipocytes, adipocytes were stained for FAS. The thin and round cytoplasm of adipocytes had a strong positive stain (100x) (B) a FAS-positive stained case, immunohistochemically, over one-third of the tumor cells were positive, which means it was counted as a FAS-positive case (100x distal bile duct cancer, adenocarcinoma) (C) a FAS-negative stained case, immunohistochemically, less than one-third of the tumor cells were positive, which means it was counted as a FAS-negative case (100x distal bile duct cancer, adenocarcinoma). defined as positive staining in less than one-third of tumor cells (Figure 1). Chemotherapy histories and prognoses were obtained from patient medical records. Statistical analysis Statistical analysis was performed using a log-rank test. All analyses were conducted using Graph Pad Prism5® statistical software (Graph Pad Software Inc., La Jolla, CA, USA). A p-value less than 0.05 was considered significant. The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the Ethical Committee of our hospital.","PeriodicalId":15170,"journal":{"name":"Journal of Cancer Science & Therapy","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer Science & Therapy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.4172/1948-5956.1000584","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: Immunohistochemical fatty acid synthase expression is a prognostic marker in several cancers and is related to cancer aggressiveness. Here, we analyzed fatty acid synthase expression as an indicator of adjuvant chemotherapy for distal bile duct and ampullary cancer cases. Methods: Forty-three cases of distal bile duct cancer and thirty-seven ampullary cancer cases resected between 2000 and 2017 were examined. We investigated immunohistochemical fatty acid synthase expression in resected specimens and the involvement of lymph nodes. We compared these findings with patient prognosis using medical history of postoperative adjuvant chemotherapy. Patient survival was expressed by the Kaplan-Meyer method and analyzed by a log-rank test. Results: There were twenty-two fatty acid synthase-positive cases for distal bile duct cancer and seventeen for ampullary cancer. For distal bile duct cancer cases, the relapse-free survival and overall survival of fatty acid synthase-positive cases were shorter than those for fatty acid synthase-negative cases (p=0.0094 and p=0.0327, respectively). For ampullary cancer cases, the relapse-free survival and overall survival of fatty acid synthasepositive cases were also shorter than those for fatty acid synthase-negative cases (p=0.0225 and p=0.0103, respectively). Adjuvant chemotherapy occurred in twelve of the twenty-two fatty acid-positive distal bile duct cancer cases and in eight of the seventeen fatty acid-positive ampullary cancer cases. Relapse-free survival and overall survival of cases with adjuvant chemotherapy did not differ from those without adjuvant chemotherapy in both distal bile duct cancer and ampullary cancer. Conclusion: Although fatty acid synthase expression was a prognostic factor in bile duct cancer and ampullary cancer, it was not an indicating marker for adjuvant chemotherapy. Citation: Maekawa H, Sato K (2019) Efficacy of Adjuvant Chemotherapy for Fatty Acid Synthase-Positive and Negative Distal Bile Duct Cancer and Ampullary Cancer: A Retrospective Analysis. J Cancer Sci Ther 11: 057-062. doi: 10.4172/1948-5956.1000584 J Cancer Sci Ther, an open access journal ISSN: 1948-5956 Volume 11(2) 057-062 (2019) 58 Figure 2: The prognoses of distal bile duct cancer according to node involvement (A) Relapse-free survival curve of node-positive and -negative cases, the relapsefree survival of node-positive cases was shorter than that of node-negative cases (50% relapse-free survival was 7 months and undefined, respectively, p=0.0002) (B) Overall survival curve of node-positive and -negative cases, there was no significant difference between node-positive cases and node-negative cases (mean survival time was 22 months and 60 months, respectively, p=0.0925). Figure 1: Immunohistochemical FAS expression (A) FAS staining of adipocytes, adipocytes were stained for FAS. The thin and round cytoplasm of adipocytes had a strong positive stain (100x) (B) a FAS-positive stained case, immunohistochemically, over one-third of the tumor cells were positive, which means it was counted as a FAS-positive case (100x distal bile duct cancer, adenocarcinoma) (C) a FAS-negative stained case, immunohistochemically, less than one-third of the tumor cells were positive, which means it was counted as a FAS-negative case (100x distal bile duct cancer, adenocarcinoma). defined as positive staining in less than one-third of tumor cells (Figure 1). Chemotherapy histories and prognoses were obtained from patient medical records. Statistical analysis Statistical analysis was performed using a log-rank test. All analyses were conducted using Graph Pad Prism5® statistical software (Graph Pad Software Inc., La Jolla, CA, USA). A p-value less than 0.05 was considered significant. The study protocol conformed to the ethical guidelines of the World Medical Association Declaration of Helsinki and was approved by the Ethical Committee of our hospital.
脂肪酸合酶阳性和阴性的远端胆管癌和壶腹癌辅助化疗的疗效回顾性分析
目的:免疫组织化学脂肪酸合成酶的表达是几种癌症的预后指标,与癌症的侵袭性有关。在这里,我们分析了脂肪酸合成酶的表达作为远端胆管癌和壶腹癌患者辅助化疗的指标。方法:回顾性分析2000 ~ 2017年间43例远端胆管癌和37例壶腹癌的临床资料。我们研究了免疫组织化学脂肪酸合成酶在切除标本中的表达和淋巴结的受累情况。我们将这些发现与患者术后辅助化疗病史的预后进行比较。患者生存率采用Kaplan-Meyer法表示,log-rank检验分析。结果:远端胆管癌脂肪酸合酶阳性22例,壶腹癌17例。在远端胆管癌病例中,脂肪酸合酶阳性患者的无复发生存期和总生存期均短于脂肪酸合酶阴性患者(p=0.0094和p=0.0327)。在壶腹癌病例中,脂肪酸合酶阳性患者的无复发生存期和总生存期也短于脂肪酸合酶阴性患者(p=0.0225和p=0.0103)。22例脂肪酸阳性的远端胆管癌病例中有12例辅助化疗,17例脂肪酸阳性的壶腹癌病例中有8例辅助化疗。在远端胆管癌和壶腹癌中,辅助化疗病例的无复发生存率和总生存率与未辅助化疗病例无差异。结论:虽然脂肪酸合酶表达是胆管癌和壶腹癌的预后因素,但它不是辅助化疗的指示性指标。引用本文:Maekawa H, Sato K(2019)脂肪酸合酶阳性和阴性的远端胆管癌和壶腹癌辅助化疗的疗效:回顾性分析。[J]中国癌症杂志,11:557 - 562。J Cancer science Ther,开放获取期刊,ISSN: 1948-5956 vol . 11(2) 057-062 (2019) 58根据淋巴结累及情况对远端胆管癌预后的影响(A)淋巴结阳性和阴性病例的无复发生存曲线,淋巴结阳性病例的无复发生存期短于淋巴结阴性病例(50%无复发生存期为7个月,未定义,p=0.0002) (B)淋巴结阳性和阴性病例的总生存曲线。淋巴结阳性和淋巴结阴性患者的平均生存时间分别为22个月和60个月,差异无统计学意义(p=0.0925)。图1免疫组化FAS表达(A)脂肪细胞FAS染色,脂肪细胞FAS染色。薄,脂肪细胞的细胞质强阳性染色(100 x) (B) FAS-positive染色情况下,免疫组织化学,超过三分之一的肿瘤细胞是积极的,这意味着它被算作一个FAS-positive案件(100 x远端胆管癌,腺癌)(C) FAS-negative染色情况下,免疫组织化学,不到三分之一的肿瘤细胞是积极的,这意味着它被算作一个FAS-negative案件(100 x远端胆管癌,腺癌)。定义为少于三分之一的肿瘤细胞呈阳性染色(图1)。化疗史和预后从患者医疗记录中获得。统计分析采用log-rank检验进行统计分析。所有分析均使用Graph Pad Prism5®统计软件(Graph Pad software Inc., La Jolla, CA, USA)进行。p值小于0.05被认为是显著的。本研究方案符合《世界医学协会赫尔辛基宣言》的伦理准则,并经我院伦理委员会批准。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信